Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp3 | Arthritis and other joint diseases: translational and clinical | ECTS2014

Bone loss in patients with early axial spondyloarthritis

Gubar Elena , Bochkova Anna , Smirnov Alexander , Dubinina Tatiana , Diomina Anastasia , Rumiantseva Oksana , Shubin Sergey , Glukhova Svetlana , Erdes Shander

Objective: To examine bone mineral density (BMD) at the femoral neck (FN) and lumbar spine (LS) in patients (pts) with early axial spondyloarthritis (axSpA).Methods: 73 pts (33 men and 40 women) with early axSpA were included in this study. Pts fulfilled ASAS criteria. Pts enrolled in the study had inflammatory back pain for < 5 years: mean disease duration 19.9±14.4 months. Mean age 28.3±6.4 years, mean BASDAI 4.1±1.9; mean ASDAS-CRP ...

ba0001pp424 | Osteoporosis: treatment | ECTS2013

Acute phase response and zoledronic acid therapy

Yureneva Svetlana , Yakushevskaya Oksana , Smetnik Vera , Sukchich Gennady

Introduction: We aimed to study acceptability of zoledronic acid in the treatment of postmenopausal osteoporosis within 3 years.Methods: Clinical, biochemical, shipping registration at poll by phone and on the subsequent visits.Results: We studied 225 patients with postmenopausal osteoporosis. The patients were treated with zoledronic acid (Zol) 5 mg as a once-yearly infusion within 3 years and 2500 mg of calcium carbonate+800 ME v...

ba0001pp423 | Osteoporosis: treatment | ECTS2013

Three years' experience of zoledronic acid use in the treatment of postmenopausal osteoporosis

Yureneva Svetlana , Yakushevskaya Oksana , Kuznetsov Sergey , Ivanets Tatyana , Smetnik Vera , Sukchich Gennady

Introduction: We aimed to study efficacy of zoledronic acid (Zol) in the treatment of postmenopausal osteoporosis within 3 years.Methods: Clinical, bone mineral density (BMD) by DEXA (L1–L4, femoral Neck) (baseline, 12, 24, and 36 months); biochemical; immunoenzyme assay of bone turnover markers (BTM) – osteocalcin (OK) β-C-terminal telopeptides of type 1 collagen (CTX) (baseline, 1, 3, 6, 9, and 12 after one, two, three infusions).<p ...

ba0003pp312 | Osteoporosis: treatment | ECTS2014

Farnesylpyrophosphate synthase rs2297480 polymorphism and the response to the zoledronic acid in the treatment of postmenopausal osteoporosis

Yureneva Svetlana , Yakushevskaya Oksana , Donnikov Andrey , Kuznetzov Sergey , Mullambaeva Svetlana , Alekseeva Marina , Trophymov Dmitry , Ivanetz Tatyana , Sukhikh Gennady

Research design and methods: A characterisation of 225 European (Russian) osteoporotic postmenopausal women, treated for 2 years with amino-bisphosphonate zoledronic acid (zol), with respect to the adenosine/cytosine (A/C) rs2297480 farnesyl pyrophosphate synthase (FDPS) gene polymorphism, was carried out by PCR-based enzymatic digestion and quantitative PCR allelic discrimination on genomic DNA extracted from blood leukocytes. The association between these polymorphism genoty...

ba0004p201 | (1) | ICCBH2015

The results of pamidronate treatment independently and in combination with surgery in patients with osteogenesis imperfecta.

Zyma Andrii , Guk Iurii , Gayko Oksana , Magomedov Oleksandr , Kinchaya-Polishchuk Tamara , Stewart David , Cheverda Andriy , Demyan Yuriy

Introduction: The effectiveness of intravenous pamidronate was assessed independently and in combination with corrective osteotomy surgery for lower extremity deformities in children with osteogenesis imperfecta.Methods: Orthopaedic treatment was conducted in 21 patients with OI (type I–ten patients, type III–11 patients), including 13 males and eight females with mean age 9.4±0.6. All patients received calcium supplements and active forms...